NEW YORK – Osteoporosis diagnostic firm Osteolabs announced Wednesday that it has entered into a strategic partnership with Swiss medical laboratory Labor Team to distribute Osteolabs' test for ...

The work will focus on addressing unmet needs in breast cancer, including the diagnosis and treatment of patients with rare cancer subtypes.

The protein biomarker-based test will be used to identify patients at high risk of cancer in order to prioritize them for conventional cancer screening methods.

The test is the last of three multiplex bloodstream infection panels that the firm has designed for its Liaison Plex molecular testing instrument.

The RiskReveal assay was used to determine which early-stage non-squamous NSCLC patients should undergo adjuvant chemotherapy ...

The three-year award from the National Institute for Health and Care Research will support finalization of the test as well as initial validation studies.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

Called Velo, the system can perform true PCR testing in 10 minutes or less and is intended for use in decentralized spaces.